Shark Tank India recently presented three founders of Kerala and Andhra Pradesh who said their invention could predict cancer and heart disease. Dr. Rajasekhara Reddy Ravuri, Dhaneesh Jameson and Tony Jose presented their business, Sugarstrings.ai, which offers health projections based on DNA. Their genetic test, powered by automatic learning, aims to detect diseases caused by genetic mutations. The trio requested 1 crore of 1 ₹ for 2.5% equity, evaluating their business at 40 crosses.
The founders said that if similar products have only 40%precision, theirs is much more precise. However, some of their most daring claims have been attenuated in the television episode. However, the terrain has left the Sharks amazed.
They said their product could identify genetic markers related to cancer and heart problems, potentially predicting these conditions of years in advance. Azhar Iqubal, co -founder of Inshorts, was visibly taken aback by these declarations.
Since its launch six months ago, Sugarstrings.ai had sold only 32 units. Among these, four customers were reported for potential risk on cancer – although the founders admitted that their predictions could only be confirmed if these people had been diagnosed later. The test costs 58,000 ₹, and when asked for their process, they explained that customers had to pass the test themselves after receiving it by Courier. This shocked Azhar, who argued that such an expensive test should be accompanied by professional assistance.
Aman Gupta has raised concerns about accuracy, especially in a country where many lack health insurance. “Samajh Nahi aa raha ki yeh authentine hoga ya naha hoga,” he said, questioning the reliability of predictions. He was also worried about false positives. “Meri toh Zindagi Kharab Ho Jayegi (my life will be over),” he said.
Vineeta Singh stressed that even if the test was not unaffordable for some, there was no evidence that this really worked. Ritesh Agarwal echoes this concern, noting that technology was still in its infancy in India. Azhar stressed that any serious medical innovation should have credible research that supports him – but the founders have not presented any scientific evidence.
Kunal Bahl saw the potential in the concept but was not convinced that he was ready for business. In the end, none of the sharks made an offer and the founders left without agreement.
